Erasca (ERAS)

• Market cap: $4.37B
• 1 day: 0.29%
• 5 days: 12.13%
• 1 month: 35.36%
• 3 months: -4.1%
• 6 months: 290.28%
• Year to date: 291.36%
• 1 year: 818.3%
• 5 years: -19.39%
• 10 years: -19.39%
• Sector: Healthcare
• Industry: Biotechnology

About: Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Employees: 103